Tratamento com daptomicina em infecção da corrente sanguínea por Enterococcus resistente a vancomicina em paciente com câncer de cólon: desfecho óbito / Treatment with daptomycin for bloodstream infection with vancomycin-resistant Enterococcus in a patient with colon cancer: death outcome

Cynthia Regina Pedrosa Soares, Vera Magalhães, Paulo Sérgio Ramos de Araújo

Abstract


Introdução: Infecção da corrente sanguínea (ICS) por Enterococcus resistente à vancomicina (VRE) é uma complicação grave em pacientes com tumor sólido. Objetivo: Descrever o aspecto clínico e molecular do isolado Enterococcus resistente a vancomicina em paciente com tumor de cólon. Métodos: O isolado de VRE foi identificado e analisado quanto ao perfil antimicrobiano a partir de hemocultura processado por método automatizado vitek®, posteriormente foi submetida para a detecção do gene de resistência à vancomicina, vanA. Resultado: O isolado Enterococcus faecium apresentou resistência à amicacina, eritromicina e vancomicina. O gene VanA foi identificado e iniciado o tratamento com teicoplanina seguida de daptomicina sem sucesso a paciente evoluiu a óbito.

 

 


Keywords


Enterococcus faecium, VRE, VanA, bacteremia, câncer.

References


Kolonen A, Sinisalo M, Huttunen R, Syrjänen J, Aittoniemi J, Huhtala H, et al. Bloodstream infections in acute myeloid leukemia patients treated according to the Finnish Leukemia Group AML-2003 protocol - a prospective nationwide study. Infect Dis (Lond). 2017; 49(11-12):799-808. doi: 10.1080/23744235.2017.1347814.

Xie O, Slavin MA, Teh BW, Bajel A, Douglas AP, Worth LJ. Epidemiology, treatment and outcomes of bloodstream infection due to vancomycin-resistant enterococci in cancer patients in a vanB endemic setting. BMC Infect Dis. 2020; 18:20(1):228. doi: 10.1186/s12879-020-04952-5.

Kamboj M, Cohen N, Huang YT et al. Impact of Empiric Treatment for Vancomycin-Resistant Enterococcus in Colonized Patients Early after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2019; 25(3):594-598. doi: 10.1016/j.bbmt.2018.11.008.

Alatorre-Fernández P, Mayoral-Terán C, Velázquez-Acosta C, Franco-Rodríguez C, Flores-Moreno K, Cevallos MÁ, et al. A polyclonal outbreak of bloodstream infections by Enterococcus faecium in patients with hematologic malignancies. Am J Infect Control. 2017; 1:45(3):260-266. doi: 10.1016/j.ajic.2016.10.002.

Teng JC, Lingaratnam SM, Trubiano JA, Thursky KA, Slavin MA, Worth LJ. Oral pristinamycin for the treatment of resistant Gram-positive infections in patients with cancer: Evaluation of clinical outcomes. Int J Antimicrob Agents. 2016; 47(5):391-6. doi: 10.1016/j.ijantimicag.2016.01.017.

Royo-Cebrecos C, Gudiol C, García J, Tubau F, Laporte J, Ardanuy C, et al. Characteristics, aetiology, antimicrobial resistance and outcomes of bacteraemic cholangitis in patients with solid tumours: A prospective cohort study. J Infect. 2017; 74(2):172-178. doi: 10.1016/j.jinf.2016.10.008.

Krull M, Klare I, Ross B, Trenschel R, Beelen DW, Todt D, et al.Emergence of linezolid- and vancomycin-resistant Enterococcus faecium in a department for hematologic stem cell transplantation. Antimicrob Resist Infect Control. 2016; 22:5-31. doi: 10.1186/s13756-016-0131-6.

Papadimitriou-Olivgeris M, Kolonitsiou F, Karamouzos V. Molecular characteristics and predictors of mortality among Gram-positive bacteria isolated from bloodstream infections in critically ill patients during a 5-year period (2012-2016). Eur J ClinMicrobiol Infect Dis. 2020; 2. doi: 10.1007/s10096-019-03803-9.

Cheah AL, Peel T, Howden BP, Spelman D, Grayson ML, Nation RL, et al. Estudo caso-caso-controle sobre fatores associados à bacteremia enterocócica resistente à vancomicina e suscetível à vancomicina. BMC Infect Dis. 2014; 14:353.

Peel T, Cheng AC, Spelman T, Huysmans M, Spelman D. Diferentes fatores de risco para bacteremia enterocócica resistente à vancomicina e sensível à vancomicina. Clin Microbiol Infect. 2012; 18(4):388–94.

Taur Y, Xavier JB, Lipuma L, Ubeda C, Goldberg J, Gobourne A, et al. Dominação intestinal e risco de bacteremia em pacientes submetidos a transplante alogênico de células-tronco hematopoiéticas . Clinical Clin Infect Dis 2012; 55:905–914. doi: 10.1093 / cid / cis580.

Amarnani R, Rapose A. Colon cancer and enterococcus bacteremia co-affection: A dangerous alliance. J Infect Public Health. 2017; 10(5):681-684. doi: 10.1016/j.jiph.2016.09.009.

Bender JK, Cattoir V, Hegstad K, Sadowy E, Coque TM, Westh H, et al. Update on prevalence and mechanisms of resistance to linezolid, tigecycline and daptomycin in enterococci in Europe: Towards a common nomenclature. Drug Resist Updat. 2018; 40:25-39. doi: 10.1016/j.drup.2018.10.002.

Lochan H, Moodley C, Rip D, Bamford C, Hendricks M, Davidson A, Eley B. Emergence of vancomycin-resistant Enterococcus at a tertiary paediatric hospital in South Africa. S Afr Med J. 2016; 9:106(6):39-43. doi: 10.7196/SAMJ.2016.v106i6.10858.

Poutsiaka DD, Skiffington S, Miller KB, Hadley S, Snydman DR. Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients. J Infect. 2007; 54(6):567-71. doi: 10.1016/j.jinf.2006.11.007.

Büyükcam A, Karada? Öncel E, Özsürekçi Y, Cengiz AB, Ku?konmaz B, Sancak B. Vancomycin-resistant Enterococcus bacteremia in a child with acute myeloid leukemia: successful treatment with daptomycin. Arch Argent Pediatr. 2016; 1;114(6):e432-e435. English, Spanish. doi: 10.5546/aap.2016.eng.e432.

Narayanan N, Rai R, Vaidya P, Desai A, Bhowmick T, Weinstein MP. Comparison of linezolid and daptomycin for the treatment of vancomycin-resistant enterococcal bacteremia. Ther Adv Infect Dis. 2019; 13;6:2049936119828964. doi: 10.1177/2049936119828964.

Britt NS, Potter EM, Patel N, Steed ME. Comparison of the Effectiveness and Safety of Linezolid and Daptomycin in Vancomycin-Resistant Enterococcal Bloodstream Infection: A National Cohort Study of Veterans Affairs Patients. Clin Infect Dis. 2015; 15;61(6):871-8. doi: 10.1093/cid/civ444. Epub 2015 Jun 10.

Ye JJ, Shie SS, Cheng CW, Yang JH, Huang PY, Wu TS, et al. Clinical characteristics and treatment outcomes of vancomycin-resistant Enterococcus faecium bacteremia. J Microbiol Immunol Infect. 2018; 51(6):705-716. doi: 10.1016/j.jmii.2017.08.025.

Shi C, Jin W, Xie Y, Zhou D, Xu S, Li Q, Lin N. Efficacy and safety of daptomycin versus linezolid treatment in patients with vancomycin-resistant enterococcal bacteraemia: An updated systematic review and meta-analysis. J Glob Antimicrob Resist. 2020; 21:235-245. doi: 10.1016/j.jgar.2019.10.008.

Kim SG, Becattini S, Moody TU, Shliaha PV, Littmann ER, Seok R, et al. Microbiota-derived lantibiotic restores resistance against vancomycin-resistant Enterococcus. Nature. 2019; 572(7771):665-669. doi: 10.1038/s41586-019-1501-z.

Caballero S, Kim S, Carter RA, Leiner IM, Sušac B, Miller L, et al. Cooperating Commensals Restore Colonization Resistance to Vancomycin-Resistant Enterococcus faecium. Cell Host Microbe. 2017; 10;21(5):592-602.e4. doi: 10.1016/j.chom.2017.04.002.




DOI: https://doi.org/10.34119/bjhrv4n2-189

Refbacks

  • There are currently no refbacks.